Salinosporamides and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9713607-B2
Application number	US-201514794468-A
Country	US
Kind code	B2
Filing date	Jul 8, 2015
Priority date	Jun 24, 2002
Publication date	Jul 25, 2017
Grant date	Jul 25, 2017

Abstract

The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC 50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

First claim

What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound having the structure:

2. The pharmaceutical composition of claim 1 , wherein the composition further comprises sucrose.

3. The pharmaceutical composition of claim 1 , wherein the composition further comprises an anti-neoplastic agent.

4. The pharmaceutical composition of claim 3 , wherein the additional anti-neoplastic agent is selected from an antimetabolite, an alkylating agent, a plant alkaloid, an antibiotic, a hormone and an enzyme.

5. The pharmaceutical composition of claim 3 , wherein the antimetabolite is selected from methotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, hydroxyurea and 2-chlorodeoxyadenosine.

6. The pharmaceutical composition of claim 3 , wherein the alkylating agent is selected from cyclophosphamide, melphalan, busulfan, paraplatin, chlorambucil and nitrogen mustard.

7. The pharmaceutical composition of claim 3 , wherein the plant alkaloid is selected from vincristine, vinblastine, taxol and etoposide.

8. The pharmaceutical composition of claim 3 , wherein the antibiotic is selected from doxorubicin, daunorubicin, mitomycin c and bleomycin.

9. The pharmaceutical composition of claim 3 , wherein the hormone is selected from calusterone, diomostavolone, propionate, epitiostanol, mepitiostane, testolactone, tamoxifen, polyestradiol phosphate, megesterol acetate, flutamide, nilutamide and trilotane.

10. The pharmaceutical composition of claim 3 , wherein the enzyme is selected from L-asparaginase derivatives and aminoacridine derivatives.

11. The pharmaceutical composition of claim 10 , wherein the aminoacridine derivative is amsacrine.

12. The pharmaceutical composition of claim 1 , wherein the composition is useful for inhibiting a proliferation of cancer cells.

13. The pharmaceutical composition of claim 12 , wherein the cancer cells are mammalian colon cancer cells.

14. The pharmaceutical composition of claim 1 , wherein the composition is in solid form.

15. The pharmaceutical composition of claim 1 , wherein the composition is in the form of a sterile injectable solution.

16. The pharmaceutical composition of claim 1 , wherein injectable solution is an aqueous solution.

Assignees

• Univ California

Inventors

• Fenical William
• Jensen Paul
• Mincer Tracy
• Feling Robert H R

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D491/044 Primary

  with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title

• A61K31/43

  Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems · CPC title

• C12P17/18

  containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin {(e.g. Rifamycin C12P17/189)} · CPC title